Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
132.16
-0.27 (-0.20%)
At close: Dec 5, 2025, 4:00 PM EST
132.22
+0.06 (0.05%)
After-hours: Dec 5, 2025, 7:08 PM EST
Revenue Breakdown
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Innovative Medicines Revenue | 54.35B | 50.32B |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 2.02B | 1.41B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 56.37B | 51.72B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| United States Revenue (Post-Q2 2023 Reporting) | 24.00B | 21.15B |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue (Post-Q2 2023 Reporting) | 16.29B | 15.56B |
Log In |
Log In |
Log In | Upgrade
|
| Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) | 10.46B | 10.02B |
Log In |
Log In |
Log In | Upgrade
|
| Canada and Latin America Revenue (Post-Q2 2023 Reporting) | 3.60B | 3.59B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 2.02B | 1.41B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 56.37B | 51.72B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography 2
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Europe Revenue (Pre-Q3 2023 Reporting) | - | - |
Log In |
Log In |
Log In | Upgrade
|
| United States Revenue (Pre-Q3 2023 Reporting) | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Canada and Latin America Revenue (Pre-Q3 2023 Reporting) | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 56.37B | 51.72B |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 2
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Cardiovascular, Renal And Metabolic Revenue | 9.76B | 8.58B |
Log In |
Log In |
Log In | Upgrade
|
| Immunology Revenue | 9.98B | 9.29B |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Revenue | 5.66B | 4.75B |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue | 16.51B | 14.74B |
Log In |
Log In |
Log In | Upgrade
|
| Established Brands Revenue | 12.45B | 12.96B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 56.37B | 51.72B |
Log In |
Log In |
Log In | Upgrade
|
Gross Profit
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Innovative Medicines Gross Profit | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz Gross Profit | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Gross Profit | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Gross Profit (Other) | 42.96B | 38.90B |
Log In |
Log In |
Log In | Upgrade
|
| Gross Profit (Total) | 42.96B | 38.90B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Innovative Medicines Operating Profit | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz Operating Profit | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Operating Profit | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | 17.56B | 14.54B |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 17.56B | 14.54B |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Cosentyx Revenue | 6.46B | 6.14B |
Log In |
Log In |
Log In | Upgrade
|
| Gilenya Revenue | - | 552.00M |
Log In |
Log In |
Log In | Upgrade
|
| Entresto Revenue | 8.68B | 7.82B |
Log In |
Log In |
Log In | Upgrade
|
| Tasigna Revenue | 1.34B | 1.67B |
Log In |
Log In |
Log In | Upgrade
|
| Lucentis Revenue | 720.00M | 1.04B |
Log In |
Log In |
Log In | Upgrade
|